

## DAFTAR PUSTAKA

- Ades, F., Zardavas, D., Pinto, A.C., Criscitiello, C., Aftimos, P., de Azambuja, E. (2014). Cardiotoxicity of systemic agents used in breast cancer. *The Breast*. 23(4):317–328. doi:10.1016/j.breast.2014.04.002
- Asharianti, A. (2019). Manajemen Kanker Payudara Komprehensif. Surabaya
- Bando, S., Soeki, T., Matsuura, T., Tobiume, T., Ise, T., Kusunose, K., Yamaguchi, K., *et al.* (2017). Plasma brain natriuretic peptide levels are elevated in patients with cancer. *PLoS ONE* 12(6): e0178607. doi:10.1371/journal.pone.0178607
- Barish, R., Lynce, F., Unger, K., Barac, A. (2019). Management of Cardiovascular Disease in Women With Breast Cancer. *Circulation*. 139:1110–1120. doi:10.1161/CIRCULATIONAHA.118.039371
- Bay, M., Kirk, V., Parner, J., Hassager, C., Nielsen, H., Krogsgaard, K., Trawinski, J., Boesgaard, S., Aldershvile, J. (2003). NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. *Heart*. 89:150–154. doi:10.1136/heart.89.2.150
- Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., *et al.* (2015) Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. *Circulation*, 131(22):1981–1988. doi:10.1161/circulationaha.114.013777
- Cardinale, D., Iacopo, F., Cipolla, C.M. (2020). Cardiotoxicity of Anthracyclines. *Front Cardiovasc. Med*. 7:26. doi: 10.3389/fcvm.2020.00026
- Cavallari, I., Maddaloni, E., Pieralice, S., Mulè, M.T., Buzzetti, R., Ussia, G.P., Pozzilli, P., Grigioni, F. (2020). The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments. *J Clin Endocrinol Metab*. 105(9): e3075–e3089. doi:10.1210/clinem/dgaa427
- Chatterjee, K., Zhang, J., Honbo, N., Karliner, J.S. (2010). Doxorubicin Cardiomyopathy. *Cardiology*. 115:155–162. doi:10.1159/000265166
- Chaudry, M., Banchs, J., ChavezMacGregor, M. (2016). Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?. *Biomark Med*. 10(3):315–328. doi:10.2217/bmm.15.124
- Chung, W.B., Yi, J.E., Jin, J.Y., Choi, Y.S., Park, C.S., Park, W.C., Song, B.J., Youn, J. (2013). Early Cardiac Function Monitoring for Detection of Subclinical Doxorubicin Cardiotoxicity in Young Adult Patients with Breast Cancer. *J Breast Cancer*. 16(2):178–183. doi:10.4048/jbc.2013.16.2.178
- Chung, W.B., Youn, H.J. (2016). Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. *Korean J Intern Med*. 31(4):625–633. doi:10.3904/kjim.2016.017
- Cil, T., Kaplan, A.M., Altintas, A., Akin, A.M., Alan, S., Isikdogan, A. (2009). Use of N-Terminal Pro-Brain Natriuretic Peptide to Assess Left Ventricular Function after Adjuvant Doxorubicin Therapy in Early Breast

- Cancer Patients A Prospective Series. *Clin Drug Invest.* 29(2):131-137. doi:10.2165/0044011-200929020-00007
- Curiati M.N.C., Silvestre O.M., Pires L.J., Mangini S., Pires P.V., Gaiotto F.A., Laurino A.M., Pêgo-Fernandes P.M., Ferreira C.E., Bacal F. (2013). Agreement of BNP and NT-proBNP and the influence of clinical and laboratory variables. *Einstein.* 11(3):273-7. doi:10.1590/s1679-45082013000300003
- Dahlan, M.S. (2010). Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan 3rd ed. Jakarta: Salemba Medika.
- Demissei, B.G., Hubbard, R.A., Zhang, L., Smith, A.M., Sheline, K., Mc Donald, C., Narayan, V., Domchek, S.M., De Michele, A., et al. (2020). Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. *J Am Heart Assoc.* 9:e014708. doi:10.1161/JAHA.119.014708
- Dong, Y., Wu, Q., Hu, C. (2022). Early Predictive Value of NT-proBNP Combined With Echocardiography in Anthracyclines Induced Cardiotoxicity. *Front Surg.* 9:898172. doi: 10.3389/fsurg.2022.898172
- Felker, G.M., Petersen, J.W., Mark, D.B. (2006). Natriuretic peptides in the diagnosis and management of heart failure. *Canadian Medical Association Journal*, 175(6):611–617. doi:10.1503/cmaj.060236
- Florescu, M., Cinteza, M., Vinereanu, D. (2013). Chemotherapy-induced Cardiotoxicity. *Journal of Clinical Medicine.* 8(1):59-67
- Hammerer-Lercher, A., Puschendorf, B., Mair, J. (2006). B-type natriuretic peptides as powerful markers in cardiac diseases – analytical and clinical aspects. *J Lab Med.* 30(3):165–184. doi:10.1515/jlm.2006.017
- Henriksen, P.A. (2018). Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. *Heart.* 104:971–977. doi:10.1136/heartjnl-2017-312103
- Igarashi, M., Jimbu, Y., Hirata, A., Tominaga, M. (2005). Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes. *Endocrine Journal.* 52(3):353–362. doi:10.1507/endocrj.52.353
- Isbandiyah. (2011). Brain Natriuretic Peptide (BNP). *UMM Scientific Journals.* 7(15).
- Kabore, E.G., Guenancia, C., Vaz-Luis, I., Di Meglio, A., Pistilli, B., Coutant, C., Cottu, P., Lesur, A., Petit, T., Dalenc, F., et al. (2019). Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. *PLoS Med.* 16(12):e1002989. doi:10.1371/journal.pmed.1002989
- Kamelia, T., Waspadji, S., Makmun, L.H., Effendi, S., Ramli, M., Timan, IS. (2017). Perubahan Konsentrasi Amino Terminal Pro B-Type Natriuretic Peptide (NT-proBNP) dan Fraksi Ejeksi Ventrikel Kiri pada Pasien Kemoterapi Doksorubisin. *Jurnal Penyakit Dalam Indonesia.* 4(2).
- Kasper, D.L., Longo, D.L., Fauci, A.S. (2016). Breast Cancer. In: Harrison Principle of Internal Medicine. 19th ed. London. McGraw-Hill:316-321

- Kasznicki, J., Drzewoski, J. (2014). Heart failure in the diabetic population – pathophysiology, diagnosis and management. *Arch Med Sci.* 10(3):546-556. doi:10.5114/aoms.2014.43748
- Khairunnisa, Hariyanto, D., Herman, R.B. (2020). Korelasi Kadar NT- proBNP dengan Fungsi Fraksi Ejeksi Ventrikel Kiri pada Gagal Jantung Anak. *Sari Pediatri.* 22(1):30-36
- Kittiwarawut, A., Vorasettakarnkij, Y., Tanasanvimon, S., Manasnayakorn, S., Sriuranpong, V. (2012). Serum Nt-ProBNP In The Early Detection Of doxorubicin-induced cardiac dysfunction. *Asia-Pac J Clin Oncol.* 9(2):155-161. doi:10.1111/j.1743-7563.2012.01588.x
- Lotrionte, M., Biondi-Zoccai, G., Abbate, A., Lanzetta, G., D’Ascenzo, F., Malavasi, F., Peruzzi, M., Frati, G., Palazzoni, G. (2013). Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity. *Am J Cardiol.* 112(12):1980–1984. doi:10.1016/j.amjcard.2013.08.026
- Lu, X., Zhao, Y., Chen, C., Han, C., Xue, L., Xing, D., Huang, O., Tao, M. (2019). BNP as a marker for early prediction of anthracycline- induced cardiotoxicity in patients with breast cancer. *Oncology Letters.* 18:4992-5001. doi:10.3892/ol.2019.10827
- McGowan, J.V., Chung, R., Maulik, A., Piotrowska, I., Walker, J.M., Yellon, D.M. (2017). Anthracycline Chemotherapy and Cardiotoxicity. *Cardiovasc Drugs Ther.* 31:63–75. doi:10.1007/s10557-016-6711-0
- Michel, L., Rassaf, T., Totzeck, M. (2018). Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. *J Thorac Dis.* 10(S35):S4282-S4295. doi: 10.21037/jtd.2018.08.15
- Mohammed, T., Singh, M., Tiu, J.G., Kim, A.S. (2021). Etiology and management of hypertension in patients with cancer. *Cardio-Oncology.* 7:14. doi:10.1186/s40959-021-00101-2
- Nadar, S.K., Shaikh, M.M. (2019). Biomarkers in Routine Heart Failure Clinical Care. *Cardiac Failure Review.* 5(1):50–56. doi: 10.15420/cfr.2018.27.2
- Nicolazzi, M.A., Carnicelli, A., Fuorlo, M., Scaldaferri, A., Masetti, R., Landolfi, R., Favuzzi, AMR. (2018). Anthracycline And Trastuzumab-Induced cardiotoxicity in breast cancer. *Eur Rev Med Pharmac Sci.* 22(7):2175-2185. doi:10.26355/eurrev\_201804\_14752
- Perez, I.E., Alam, S.T., Hernandez, G.A., Sancassani, R. (2019). Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. *Clinical Medicine Insights: Cardiology.* 13:1–11. doi:10.1177/1179546819866445
- Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G.F., Coats, A.J.S., et al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *European Heart Journal.* 37(27):2129–2200. doi:10.1093/eurheartj/ehw128
- Registrasi Kanker Berbasis (RKB) RS Dr. Sardjito/ FK-KMK UGM. <https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/rkbr-maret-2021/>

- Romano, S., Fratini, S., Ricevuto, E., Procaccini, V., Stifano, G., Mancini, M., Mauro, M.D., Ficorella, C., Penco, M. (2011). Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. *British Journal of Cancer*. 105(11):1663–1668. doi:10.1038/bjc.2011.439
- Rosano, G.M.C., Vitale, C., Seferovic, P. (2017). Heart Failure in Patients with Diabetes Mellitus. *Cardiac Failure Review*. 3(1):52–5. doi:10.15420/cfr.2016:20:2
- Rüger, A. M., Schneeweiss, A., Seiler, S., Tesch, H., van Mackelenbergh, M., Marmé, F., et al. (2020). Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial. *J Am Heart Assoc*. 9(23). doi:10.1161/JAHA.120.018143
- Saha, S., Singh, P.K., Roy, P., Kakar, S.S. (2022). Cardiac Cachexia: Unaddressed Aspect in Cancer Patients. *Cells*. 11(6):990. <https://doi.org/10.3390/cells11060990>
- Sawyer, D.B., Peng, X., Chen, B., Pentassuglia, L., Lim, C.C. (2010). Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?. *Prog Cardiovasc Dis*. 53(2):105–113. doi:10.1016/j.pcad.2010.06.007
- Shah, R., Rosso, K., Nathanson, S.D. (2014). Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World J Clin Oncol*. 5(3):283-298. doi:10.5306/wjco.v5.i3.283
- Sulaiman, L., Hesham, D., Hamid, M.A., Youssef, G. (2021). The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients. *The Egyptian Heart Journal*. 73(1):20. doi 10.1186/s43044-021-00142-z
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 71:209-249. doi: 10.3322/caac.21660
- Sweeney, M., Yiu, A., Lyon, A.R. (2017). Cardiac Atrophy and Heart Failure In Cancer. *Cardiac Failure Review*. 3(1):62–65. doi:10.15420/cfr.2017:3:2
- Tadic, M., Cuspidi, C., (2017). The Role of Echocardiography in Detection of Chemotherapy-Induced Cardiotoxicity in Breast Cancer Patients. *Int J Cancer Manag*. 10(5):e8109. doi: 10.5812/ijcm.8109
- Tan, T.C., Scherrer-Crosbie, M. (2012). Assessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography. *Curr Cardiovasc Imaging Rep*. 5(6): 403–409. doi:10.1007/s12410-012-9163-3
- Tian, S., Hirshfield, K.M., Jabbour, S.K., Toppmeyer, D., Haffty, B.G., Khan, A.J., Goyal, S. (2014). Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. *Frontiers in Oncology*. 4. doi:10.3389/fonc.2014.00277
- Toblli, J.E., Lombraña, A., Duarte, P., Gennaro, F.D. (2007). Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency. *J Am Coll Cardiol*. 50(17):1657-1665. doi: 10.1016/j.jacc.2007.07.029

- Vaitiekus, D., Muckiene, G., Vaitiekiene, A., Maciulienė, D., Vaiciulienė, D., Ambrazeviciute, G., Sereikaite, L., et al. (2019). Impact of Arterial Hypertension on Doxorubicin-Based Chemotherapy-Induced Subclinical Cardiac Damage in Breast Cancer Patients. *Cardiovascular Toxicology*. doi:10.1007/s12012-019-09556-3
- Van Boxtel, W., Bulten, B.F., Mavinkurve-Groothuis, A.M.C., Bellersen, L., Mandigers, C.M.P.W., Joosten, L.A.B., Kapusta, L., et al. (2015). New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. *Biomarkers*. 20(2):143-148 doi:10.3109/1354750X.2015.1040839
- Varricchi, G., Ameri, P., Cadeddu, C., Ghigo, A., Madonna, R., Marone, G., Mercurio, V., Monte, I., Novo, G., Parrella, P., Pirozzi, F., et al. (2018). Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. *Front Physiol*. 9:167. doi: 10.3389/fphys.2018.00167
- Waks, A.G., Winer, E.P. (2019). Breast Cancer Treatment A Review. *JAMA*. 321(3):288-300. doi:10.1001/jama.2018.19323
- Zamorano, J.L., Lancellotti, P., Muñoz, D.R., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, et al. (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. *European Heart Journal*. 37(26):2768–2801. doi:10.1093/eurheartj/ehw211
- Zhang, M., Yang, H., Xu, C., Jin, F., Zheng, A. (2022). Risk Factors for Anthracycline Induced Cardiotoxicity in Breast Cancer Treatment: A Meta-Analysis. *Front Oncol*. 12:899782. doi: 10.3389/fonc.2022.899782